Biosynex SA (EPA:ALBIO)
France · Delayed Price · Currency is EUR 1.050
-0.010 (-0.94%)
May 29, 2026, 5:35 PM CET
Biosynex Revenue
In the year 2025, Biosynex had annual revenue of 115.13M EUR with 13.80% growth. Biosynex had revenue of 50.53M in the half year ending June 30, 2025, with 18.46% growth.
Revenue
115.13M
Revenue Growth
-7.14%
P/S Ratio
0.17
Revenue / Employee
253.59K
Employees
454
Market Cap
19.69M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 115.13M | 13.96M | 13.80% |
| Dec 31, 2024 | 101.17M | 8.19M | 8.81% |
| Dec 31, 2023 | 92.98M | -103.61M | -52.70% |
| Dec 31, 2022 | 196.59M | -185.95M | -48.61% |
| Dec 31, 2021 | 382.53M | 228.64M | 148.57% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Guerbet | 798.67M |
| Diagnostic Medical Systems | 49.47M |
| Median Technologies | 23.47M |
| Novacyt | 22.96M |
| Implanet | 12.47M |
| Bluelinea Société Anonyme | 11.12M |
| Mauna Kea Technologies | 8.91M |
| SpineGuard | 3.76M |